NEW YORK (GenomeWeb) – Within a large pharmacogenetic study ongoing at several Indiana institutions, researchers are aiming to tackle the issues that have kept personalized medicine approaches from reaching disadvantaged communities.

Earlier this month, Eskenazi Health, the Indiana Institute for Personalized Medicine (IIPM), the Indiana University School of Medicine, and the Regenstrief Institute announced the launch of a 6,000-patient prospective trial to study the impact of preemptive pharmacogenetic testing in a community healthcare setting.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Union of Concerned Scientists surveyed US government scientists about Trump Administration policies and more, Science reports.

National Geographic reports that marine mammals have lost a gene that could make them more susceptible to organophosphate damage.

NPR reports on Human Cell Atlas Consortium's effort to catalog all the different cell types within the human body.

In PNAS this week: history and genetic diversity of the scarlet macaw, approach for predicting human flu virus evolution, and more.